自拟骨八方对股骨干骨折瘀热证及炎症介质影响的研究
|
摘要
目的观察骨八方对闭合性股骨干骨折早期瘀热证型的临床疗效,及其对IL-1、IL-6、TNF-a三种炎性因子的调节作用,并进一步探讨骨八方的作用机制。
方法自2009年8月至2010年2月在佛山市中医院住院治疗闭合性股骨干骨折患者中,选取符合纳入标准而无排除标准的病例60例。男46例、女14例,年龄20-50岁,平均36.8±2.6岁；受伤部位：左侧30例、右侧30例；伤后至就诊时间为6.5±1.5小时。按照分层随机化的方法分成骨八方组、桃红四物汤组、常规治疗组3组。骨八方组从入院第1天开始每天给予骨八方一剂,结合基础治疗,连续给药7天；桃红四物汤组从入院第1天开始每天给予桃红四物汤一剂,结合基础治疗,连续给药7天；常规治疗组每天给予基础治疗,连续7天。每组患者在入院第1天(给药前)第3天、第5天、第7天采集瘀热证临床症状积分并检验IL-1、IL-6、TNF-a血清学水平,比较三组第1天(给药前)、第3天、第5天、第7天瘀热证临床症状积分,IL-1、IL-6、TNF-a血清学水平,并进一步分析瘀热证临床症状积分与IL-1、IL-6、TNF-a血清学水平的相关性。
结果三组第1天瘀热证临床症状积分比较无显著性差异,具有可比性；第3天、第5天、第7天三组瘀热症状积分中,骨八方最低、桃红四物汤次之,常规治疗组最高,差异具有统计学意义(P<0.05),但是桃红四物汤组与常规组比较差异无统计学意义(P>0.05)。第3天、第5天、第7天三组瘀热症状积分中便秘、肿胀积分比较显示骨八方组积分最低,与桃红四物汤组、常规组比较差异具有统计学意义(P<0.05)。三组炎性因子IL-1、IL-6、TNF-a水平第1天比较无显著性差异,第3天、第5天、第7天骨八方与常规组、桃红四物汤组比较差异有统计学意义(P<0.05)。骨八方组、常规组的IL-1、IL-6、TNF-a血清学水平与两组瘀热证临床症状积分作多重线性回归分析,结果筛选出两组的IL-6、TNF-a分别与两组瘀热证临床症状积分呈正相关性。骨八方组IL-6、TNF-a与瘀热证临床症状积分的相关系数r分别为(0.548、0.7650),常规组的相关系数分别为(0.5170、0.2510),结果有统计学意义(P<0.05),两组中的IL-1均无统计学意义,被删除。
结论本研究认为,骨八方选药精当、配伍合理,能明显改善瘀热型股骨干骨折早期临床症状,在一定程度调节IL-1、IL-6、TNF-a血清学水平,并且进一步研究发现瘀热证积分变化与IL-6、TNF-a三种炎症因子水平存在正相关关系,推断骨八方的作用机制可能与调节IL-6、TNF-a血清学水平有关。
Objective To observe the clinic effect of Gu Ba decoction in treating the Stagnated Heat syndrome on the early stage of closed femoral shaft fractures and its impact on IL-1, IL-6, TNF-a. Furthermore, explore the machanism of Gu Ba decoction in treating the Stagnated Heat syndrome.
Methods From August 2009 to February 2010,60 patients with closed femoral shaft fracture were employed to made study in Foshan hospital of traditional Chinese medicine, according to the inclusion criteria and exclusion criteria.Male 46 cases,14 female, aged 20-50 years, mean age 36.8±2.6 years; injured parts:the left legs of 30 cases,30 cases of right; the mean time from injury to treatment was 6.5±1.5 hours.60 patients were randomized into Gu Ba decoction group, TaoHongSiWu decoction group, conventional therapy group in accordance with the method of stratified randomization. The patients of GuBa decoction group were treated with GuBa decoction one day at a time, combined with basic therapy from the first day, and the course of treatment was 7 days; Tao Hong Si Wu decoction group were treated with Tao Hong Si Wu decoction; and similar with GuBa decoction group. Conventional treatment group were only given basic treatment for 7 days. The symptom scores of the Stagnated Heat syndrome were collected and the IL-1, IL-6, TNF-a serum levels were tested on the first day after admission (before administration), the third day, the fifth day and the seventh day in each patient, compared the clinical symptom scores and IL-1, IL-6, TNF-a serum levels, and further analysed the correlation between the Clinical symptom scores and the IL-1, IL-6, TNF-a serum level.
Results The clinical symptom scores were of no significant difference and comparable between three group on the first day; but the scores in the GuBa decoction group was lowest, the TaoHongSiWu decoction was the second, the conventional treatment group was the highest on the third day, the fifth day, the seventh day. the difference was of significant (P＜0.05), but the Taohongsiwu decoction group compared with the conventional group showed no significant difference (P> 0.05). The constipation and swelling scores in GuBa decoction showed the lowest points, and the result was significant in comparing conventional group and the TaoHongSiWu decoction group (P<0.05). The inflammatory cytokines of IL-1, IL-6, TNF-a levels in threen group was of no significant difference on first day. On the third, the fifth and the seventh day, GuBa decoction group compared with Taohongsiwu decoction group and the conventional group showed significant difference(P<0.05). The multiple linear regression and multiple correlation analysis showed positive correlation between IL-6, TNF-a serum levels and Stagnated Heat syndrome scores of GuBa decoction group and TaoHongSiWu decoction group. The correlation coefficient r in GuBa decoction were (0.548、0.7650) respectively, the coefficient in the conventional group were(0.5170、0.2510)respectively, and the results were statistically significant in two group (P<0.05), However, IL-1 in the two groups were not statistically significant, was deleted.
Conclusion The study suggests that GuBa decoction, with appropriate drug selection, reasonable compatibility, can significantly improve the clinical symptom of the Stagnated Heat syndrome in the early stage of the femoral shaft fractures, regulate IL-1, IL-6, TNF-a serum levels to some extend. Furthermore, this study finds a positive correlation between IL-6, TNF-a serum levels and Stagnated Heat syndrome scores, and infers that theIL-6, TNF-a may be the microscopic pathology material basis of Stagnated Heat syndrome, concludes that the mechanism of Gu Ba Fang's effect may relate with the regulation of IL-6, TNF-a serum levels.
方法自2009年8月至2010年2月在佛山市中医院住院治疗闭合性股骨干骨折患者中,选取符合纳入标准而无排除标准的病例60例。男46例、女14例,年龄20-50岁,平均36.8±2.6岁；受伤部位：左侧30例、右侧30例；伤后至就诊时间为6.5±1.5小时。按照分层随机化的方法分成骨八方组、桃红四物汤组、常规治疗组3组。骨八方组从入院第1天开始每天给予骨八方一剂,结合基础治疗,连续给药7天；桃红四物汤组从入院第1天开始每天给予桃红四物汤一剂,结合基础治疗,连续给药7天；常规治疗组每天给予基础治疗,连续7天。每组患者在入院第1天(给药前)第3天、第5天、第7天采集瘀热证临床症状积分并检验IL-1、IL-6、TNF-a血清学水平,比较三组第1天(给药前)、第3天、第5天、第7天瘀热证临床症状积分,IL-1、IL-6、TNF-a血清学水平,并进一步分析瘀热证临床症状积分与IL-1、IL-6、TNF-a血清学水平的相关性。
结果三组第1天瘀热证临床症状积分比较无显著性差异,具有可比性；第3天、第5天、第7天三组瘀热症状积分中,骨八方最低、桃红四物汤次之,常规治疗组最高,差异具有统计学意义(P<0.05),但是桃红四物汤组与常规组比较差异无统计学意义(P>0.05)。第3天、第5天、第7天三组瘀热症状积分中便秘、肿胀积分比较显示骨八方组积分最低,与桃红四物汤组、常规组比较差异具有统计学意义(P<0.05)。三组炎性因子IL-1、IL-6、TNF-a水平第1天比较无显著性差异,第3天、第5天、第7天骨八方与常规组、桃红四物汤组比较差异有统计学意义(P<0.05)。骨八方组、常规组的IL-1、IL-6、TNF-a血清学水平与两组瘀热证临床症状积分作多重线性回归分析,结果筛选出两组的IL-6、TNF-a分别与两组瘀热证临床症状积分呈正相关性。骨八方组IL-6、TNF-a与瘀热证临床症状积分的相关系数r分别为(0.548、0.7650),常规组的相关系数分别为(0.5170、0.2510),结果有统计学意义(P<0.05),两组中的IL-1均无统计学意义,被删除。
结论本研究认为,骨八方选药精当、配伍合理,能明显改善瘀热型股骨干骨折早期临床症状,在一定程度调节IL-1、IL-6、TNF-a血清学水平,并且进一步研究发现瘀热证积分变化与IL-6、TNF-a三种炎症因子水平存在正相关关系,推断骨八方的作用机制可能与调节IL-6、TNF-a血清学水平有关。
Objective To observe the clinic effect of Gu Ba decoction in treating the Stagnated Heat syndrome on the early stage of closed femoral shaft fractures and its impact on IL-1, IL-6, TNF-a. Furthermore, explore the machanism of Gu Ba decoction in treating the Stagnated Heat syndrome.
Methods From August 2009 to February 2010,60 patients with closed femoral shaft fracture were employed to made study in Foshan hospital of traditional Chinese medicine, according to the inclusion criteria and exclusion criteria.Male 46 cases,14 female, aged 20-50 years, mean age 36.8±2.6 years; injured parts:the left legs of 30 cases,30 cases of right; the mean time from injury to treatment was 6.5±1.5 hours.60 patients were randomized into Gu Ba decoction group, TaoHongSiWu decoction group, conventional therapy group in accordance with the method of stratified randomization. The patients of GuBa decoction group were treated with GuBa decoction one day at a time, combined with basic therapy from the first day, and the course of treatment was 7 days; Tao Hong Si Wu decoction group were treated with Tao Hong Si Wu decoction; and similar with GuBa decoction group. Conventional treatment group were only given basic treatment for 7 days. The symptom scores of the Stagnated Heat syndrome were collected and the IL-1, IL-6, TNF-a serum levels were tested on the first day after admission (before administration), the third day, the fifth day and the seventh day in each patient, compared the clinical symptom scores and IL-1, IL-6, TNF-a serum levels, and further analysed the correlation between the Clinical symptom scores and the IL-1, IL-6, TNF-a serum level.
Results The clinical symptom scores were of no significant difference and comparable between three group on the first day; but the scores in the GuBa decoction group was lowest, the TaoHongSiWu decoction was the second, the conventional treatment group was the highest on the third day, the fifth day, the seventh day. the difference was of significant (P＜0.05), but the Taohongsiwu decoction group compared with the conventional group showed no significant difference (P> 0.05). The constipation and swelling scores in GuBa decoction showed the lowest points, and the result was significant in comparing conventional group and the TaoHongSiWu decoction group (P<0.05). The inflammatory cytokines of IL-1, IL-6, TNF-a levels in threen group was of no significant difference on first day. On the third, the fifth and the seventh day, GuBa decoction group compared with Taohongsiwu decoction group and the conventional group showed significant difference(P<0.05). The multiple linear regression and multiple correlation analysis showed positive correlation between IL-6, TNF-a serum levels and Stagnated Heat syndrome scores of GuBa decoction group and TaoHongSiWu decoction group. The correlation coefficient r in GuBa decoction were (0.548、0.7650) respectively, the coefficient in the conventional group were(0.5170、0.2510)respectively, and the results were statistically significant in two group (P<0.05), However, IL-1 in the two groups were not statistically significant, was deleted.
Conclusion The study suggests that GuBa decoction, with appropriate drug selection, reasonable compatibility, can significantly improve the clinical symptom of the Stagnated Heat syndrome in the early stage of the femoral shaft fractures, regulate IL-1, IL-6, TNF-a serum levels to some extend. Furthermore, this study finds a positive correlation between IL-6, TNF-a serum levels and Stagnated Heat syndrome scores, and infers that theIL-6, TNF-a may be the microscopic pathology material basis of Stagnated Heat syndrome, concludes that the mechanism of Gu Ba Fang's effect may relate with the regulation of IL-6, TNF-a serum levels.
引文
[1]金惠铭,王建枝主编.病理生理学[M],第6版.北京：人民卫生出版社,2004：191.
[2]Marik P E, Zaloga G P. Hypothermia and cytokines in septicshock. Norasept II study investigators. North American study of the safety and efficacy of murine monoclonal antibody to tumor necrosis factor for the treatment of septic shock. Intensive Care Med,2000,26:7169-7211.
[3]TalmorM, Hydo L, Barie P S. Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in criticalsurgical illness. A rch Surg,1999,134:869-871.
[4]Haupt W, Willim A, Xiao LS, et al. Selective cytokein release induced serum and system plasma from sesptic patients. Eur J Surg,1996,162,769-776.
[5]侯文远.重度创伤患者细胞因子变化及临床意义[J].中国实用医药,2008,3(21)：10-11.
[6]郎中兵,文亮.严重创伤后血清内毒素、TNF-az、IL-1β、IL-6、IL-8的变化[J].重庆医学,2003,(32)12：1679-1681.
[7]王玉琦,叶建荣.血管外科治疗学[M].上海：上海科学技术出版社,2003,216-217.
[8]Paffen E, Vos HL, Bertina RM. Creactive protein does not directly induce tissue factor in human monocytes[J]. A rterioscler Thromb VascB iol,2004,24(5):975-981.
[9]张玥,刘效敏.深静脉血栓形成患者血清TNF-α、IL-6、IL-10水平变化及意义[J].放射免疫学杂志,2007,20(1)：13-14.
[10]张玥.炎性细胞因子在深静脉血栓形成中的作用[J].中国中西医结合外科杂志,2006,12(6)：590-592.
[11]卫俊杰,刘华.IL-6水平检测与重症并发感染者的相关性研究[J].现代检验医学杂志,2008,23(6)：92-94.
[12]田玉科,罗爱林.重度创伤后血清肿瘤坏死因子a及白细胞介素6水平变化与感染性并发症的关系[J].中华实验外科杂志,1999,16(1)：38-39.
[13]毛一雷,秦应之.抗介质治疗在全身炎症反应综合征中的应用现状[J].辽宁医学 杂志,2002,16(3)：121-122.
[14]CohenJ, CarletJ. INTERSEPT:aninternational, multicenter, placebo-controll ed trail of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis[J]. Crit Care Med,1996,24:1431-1440.
[15]Fisher CJ Jr, Dhainant JF, Opal SM, et al. Recombinant human interleukin-1 recepor antagonist in the treatment of patients with sepsis syndrome[J], JAMA,1994,27:1836-1843.
[16]Fisher CJ Jr, Agosti JM, Opal SM. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group[J]. N Engl J Med,1996,334:1697-1702.
[17]Lonnemann G, Bechstein M, Linnenweber S, et al. Tumor necrosis factor-alpha during continuous high 2 flux hemodialysis in sepsis with acute renal failure[J]. Kidney Int,1999,72(Suppl):S84-87.
[18]龙海波,林跃萍,张训,等.免疫吸附特异性清除循环肿瘤坏死因子-α对内毒素休克时心脏损伤的保护作用[J].中国危重病急救医学,1999,11(8)：477-480.
[19]Schetz MR. Classical and alternative indication for continuous renal replacement therapy[J]. Kidnry Int,1998,53(Suppl):S129-132.
[20]Christman JW, Lancaster LH,Blackwell TS. Nuclear factor 2kappa B:a pivotal role in the systemic inflammatory response syndrome and new target for therapy [J]. Intensive Care Med,1998,24:1131-1138.
[21]杨新军,吴广礼.全身炎症反应综合征的治疗现状[J].华北国防医药,2003,(15)5：318-320.
[22]巢元方.诸病源候论[M].北京：中医古籍出版社,1992：1377.
[23]王冰撰注.灵枢经[M].北京：中医古籍出版社,1997：40.
[24]张仲景.伤寒论[M].北京：人民卫生出版社,1993：8.
[25]郭立中,周仲瑛.瘀热相搏证的提出及对中医临床实践的指作用,南京中医药大学学报[J],2006,22(3)：137-139.
[26]周仲瑛,瘀热相搏证的系列研究(一)[J].天津中医药大学学报,2008,(27)3：151-155.
[27]周仲瑛,瘀热相搏证的系列研究(二)[J].天津中医药大学学报,2008,(27)4：237-240.
[28]周仲瑛.论瘀热[J],南京中医药大学学报,2006(22)5：273-276.
[29]王昀，许立.中医瘀热证临床客观评价指标研究概况[J],江苏中医药,2009,(41)5：76-78.
[30]沈庆法,杨爱东.温病气分证与微观血瘀相关性的实验研究[J].中国中医药科 技,2001,8(4)：206-209.
[31]曹书华.血必净对感染性多器官功能障碍综合征大鼠组织及内皮操作保护作用的研究[J].中国危重病急救医学,2002,12(8)：489-491.
[32]杨峰,陈斌.归元创疗汤对严重创伤患者血浆内毒素、TNF-α及IL-6的影响[J].广东医学,2007,(28)5：828-830.
[33]薛长连,吴力克.骨及软组织损伤时白细胞介素-1β与白细胞介素6变化及清热活血消肿合剂的干预效应[J],中国组织工程研究与临床康复,2007,(11)41：8408-8410.
[34]薛长连,吴力克.清热活血消肿Ⅰ、Ⅱ合剂对软组织损伤白细胞介素-1β和白细胞介素-6的影响[J].中国中医骨伤科杂志,2004,(12)3：22-24.
[35]薛长连,吴力克.清热活血消肿合剂Ⅰ、Ⅱ对软组织损伤患者血清肿瘤坏死因子和C反应蛋白的影响[J].中国临床康复,2004,(20)8：4058-4059.
[36]孙国荣,肖四旺.桃红四物汤对膝关节置换术后血清IL-2、IL-6、TNF-α表达水平的影响[J].湖南中医药大学学报,2008,(28)3：32-34.
[37]蓝肇熙,马忆南.损伤血瘀证与IL26、IL210的相关性及化瘀中药对其影响的实验研究[J].四川中医,2008,(26)11：17-19.
[38]薛长连,万年宇,徐青镭.清热活血消肿Ⅰ,Ⅱ合剂改善闭合性骨伤合并软组织损伤的疼痛肿胀[J].中国临床康复,2003,7(11)：1738.
[39]魏定基.临床使用甘露醇的不良反应分析[J].临床合理药.2010,3(1)：29-30.
[40]马民,陈利国.活血止痛散治疗骨折术后肿胀90例[J].时珍国医国药,2006,17(1)：89.
[41]叶俊材,张俐,吕一.活血化瘀汤对大鼠骨折周围肌肉肿胀的影响[J].浙江中医杂志,2007,(42)9：542.
[42]高学敏等.中药学(M).中国中医药出版社(第7版),2002,345-375.
[43]吴雪晖,罗飞,谢肇.丹红注射液治疗四肢长骨骨折术后肿胀的疗效观察[J],中华中医药学刊,2008,26(4)：893-894.
[44]程卫珍,骨折创伤后便秘的中医辨证施护[J].现代中西医结合杂志,2008,17(17)：2702-2703.
[45]吕卫华,杨朝霞,龚美霞.骨折卧床患者发生便秘的原因分析及护理干预[J].中国误诊学杂志,2008,8(32)：7924-7925.
[46]吴秋萍,钱忆.骨折卧床患者便秘的原因分析与护理对策[J].现代中西医结合杂志,2009,18(18)：2196-2197.
[47]许国根,陈雯,张万光.全身炎症反应综合征患者致炎因子与抗炎因子的变化及相关性研究[J].中国急救医学,2002,(22)6：320-321.
[48]姚咏明.多器官功能障碍综合征发病机制研究新进展[J].中华急诊医学杂 志,2001,10(1)：63.
[49]李越华.中医药干预全身炎症反应综合征研究概况[J].辽宁中医杂志,2009,(36)3：89-490.
[50]蒋超.辨证分型治疗全身炎症反应综合征疗效观察[J].中国中西医结合外科杂志,2004,(11)4：245-247.
[51]郑敏宇,何颂华.全身炎症反应综合征的中西医治疗进展[J].上海中医药杂志,2007,41(3)：78-79.
[52]张永和,赵宁,宋祖军.多发性创伤后血清TNF-α、IL-1β、IL-6及IL-10变化的连续观察.中国急救医学2002,22(3)143-144.
[53]Florian Gebhard, MD, Helga Pfetsch, MSc, Geralf Steinbach, MD. tIs interleukin 6 an Early Marker of injury Severity Following Major Trauma in Humans?[J]. Aach surg,2000,135,291-295.
[54]Panagiotis V Giannoudis, Malcolm R Smith, Robert T Evans. Serum CRP and IL-6 levels after trauma not predictive of septic complication in 31 patients[J],Acta Orthop Scand,1998,69(2)184-188.
[55]石莹,王晓勇.血必净对全身炎症反应综合征的治疗作用[J],浙江中医药大学学报,2009,(33)4：497-498.
[56]高学敏等.中药学(M).中国中医药出版社(第7版),2002,166.
[57]王宇,周杰.丹参对大鼠移植肝脏再灌注损伤中TNF-α及IL-1水平的影响[J].山东大学学报,2009,47(4)：54-57.
[58]马志胜,沈文律.中药丹参、生脉治疗全身炎症反应综合征的实验研究[J].中国普外基础与临床杂志,2005,12(4)：395-397.
[59]姜莉,赵仓焕.用控制论思想看辨证论治[J].江苏中医药,2008,(40)6：16-18.
[60]章柏平,张晓云,倪健毛.严重创伤患者血工L-6、IL-8和TNF-α的动态变化[J].实用临床医学,2008,9(8)：4-8.
[61]侯文远,重度创伤患者细胞因子变化及临床意义[J].中国实用医药,2008,(3)21：10-11.
[62]汪毅,周勇.多发性创伤患者细胞因子变化及临床意义[J].现代医药卫生,2006,(22)8：1115-1116.
[63]程三放,陆宏伟,李小珍.严重创伤患者TNF、IL-6和IL-10水平的变化及其临床意义[J].陕西医学杂志2003,(32)5：407.
[64]Ten Dijke, Fu J, Schaap P, et al. Signal transduction of bone morphogenetic proteins in osteoblast differentiation[J]. J Bone Joint Surg,2003,85:34.
[65]SchafersM, Geis C, Brors D, et al. Anterograde transport of tumor necrosis factor2alpha in the intact and injured rat sciatic nerve [J]. J Neurosci,2002,22(2):536-545.
[66]陈振兵,洪光祥,王发斌.肿瘤坏死因子对周围神经损伤后感觉神经元的保护作用[J].中华手外科杂志,2000,(16)2：120-122.
[67]姚魁武,王阶.血瘀证量化诊断流行病学调查数据的主成分分析[J].辽宁中医杂志,2009,36(1)：30-32.
[68]杨超,周岩,孙晓红,等.具有中医“热毒血瘀证”表征的大鼠血液成分和流变学变化.中国比较医学杂志,2007,17(10)：607.
[69]Hayrettin Ozturk, Yusuf Yagmur, Hulya Ozturk.The prognostic importance of serum IL-lb, IL-6, IL-8and TNF-a levels compared to trauma scoring systems for early mortality in children with blunt trauma [J]. Pediatr Surg Int (2008) 24:235-239.
[70]郭奇峰,徐中和,温世锋.血清肿瘤坏死因子a及白细胞介素6水平对下肢严重创伤病情变化的预测价值[J].中国临床康复,2006,10(24)：114-116.
[71]张喜平,李昱,吴斗,等.机械性创伤患者血清IL-6、TNF-α的动态变化及其意义[J].中国急救医学,2001,(21)11：635-637.
[2]Marik P E, Zaloga G P. Hypothermia and cytokines in septicshock. Norasept II study investigators. North American study of the safety and efficacy of murine monoclonal antibody to tumor necrosis factor for the treatment of septic shock. Intensive Care Med,2000,26:7169-7211.
[3]TalmorM, Hydo L, Barie P S. Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in criticalsurgical illness. A rch Surg,1999,134:869-871.
[4]Haupt W, Willim A, Xiao LS, et al. Selective cytokein release induced serum and system plasma from sesptic patients. Eur J Surg,1996,162,769-776.
[5]侯文远.重度创伤患者细胞因子变化及临床意义[J].中国实用医药,2008,3(21)：10-11.
[6]郎中兵,文亮.严重创伤后血清内毒素、TNF-az、IL-1β、IL-6、IL-8的变化[J].重庆医学,2003,(32)12：1679-1681.
[7]王玉琦,叶建荣.血管外科治疗学[M].上海：上海科学技术出版社,2003,216-217.
[8]Paffen E, Vos HL, Bertina RM. Creactive protein does not directly induce tissue factor in human monocytes[J]. A rterioscler Thromb VascB iol,2004,24(5):975-981.
[9]张玥,刘效敏.深静脉血栓形成患者血清TNF-α、IL-6、IL-10水平变化及意义[J].放射免疫学杂志,2007,20(1)：13-14.
[10]张玥.炎性细胞因子在深静脉血栓形成中的作用[J].中国中西医结合外科杂志,2006,12(6)：590-592.
[11]卫俊杰,刘华.IL-6水平检测与重症并发感染者的相关性研究[J].现代检验医学杂志,2008,23(6)：92-94.
[12]田玉科,罗爱林.重度创伤后血清肿瘤坏死因子a及白细胞介素6水平变化与感染性并发症的关系[J].中华实验外科杂志,1999,16(1)：38-39.
[13]毛一雷,秦应之.抗介质治疗在全身炎症反应综合征中的应用现状[J].辽宁医学 杂志,2002,16(3)：121-122.
[14]CohenJ, CarletJ. INTERSEPT:aninternational, multicenter, placebo-controll ed trail of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis[J]. Crit Care Med,1996,24:1431-1440.
[15]Fisher CJ Jr, Dhainant JF, Opal SM, et al. Recombinant human interleukin-1 recepor antagonist in the treatment of patients with sepsis syndrome[J], JAMA,1994,27:1836-1843.
[16]Fisher CJ Jr, Agosti JM, Opal SM. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group[J]. N Engl J Med,1996,334:1697-1702.
[17]Lonnemann G, Bechstein M, Linnenweber S, et al. Tumor necrosis factor-alpha during continuous high 2 flux hemodialysis in sepsis with acute renal failure[J]. Kidney Int,1999,72(Suppl):S84-87.
[18]龙海波,林跃萍,张训,等.免疫吸附特异性清除循环肿瘤坏死因子-α对内毒素休克时心脏损伤的保护作用[J].中国危重病急救医学,1999,11(8)：477-480.
[19]Schetz MR. Classical and alternative indication for continuous renal replacement therapy[J]. Kidnry Int,1998,53(Suppl):S129-132.
[20]Christman JW, Lancaster LH,Blackwell TS. Nuclear factor 2kappa B:a pivotal role in the systemic inflammatory response syndrome and new target for therapy [J]. Intensive Care Med,1998,24:1131-1138.
[21]杨新军,吴广礼.全身炎症反应综合征的治疗现状[J].华北国防医药,2003,(15)5：318-320.
[22]巢元方.诸病源候论[M].北京：中医古籍出版社,1992：1377.
[23]王冰撰注.灵枢经[M].北京：中医古籍出版社,1997：40.
[24]张仲景.伤寒论[M].北京：人民卫生出版社,1993：8.
[25]郭立中,周仲瑛.瘀热相搏证的提出及对中医临床实践的指作用,南京中医药大学学报[J],2006,22(3)：137-139.
[26]周仲瑛,瘀热相搏证的系列研究(一)[J].天津中医药大学学报,2008,(27)3：151-155.
[27]周仲瑛,瘀热相搏证的系列研究(二)[J].天津中医药大学学报,2008,(27)4：237-240.
[28]周仲瑛.论瘀热[J],南京中医药大学学报,2006(22)5：273-276.
[29]王昀，许立.中医瘀热证临床客观评价指标研究概况[J],江苏中医药,2009,(41)5：76-78.
[30]沈庆法,杨爱东.温病气分证与微观血瘀相关性的实验研究[J].中国中医药科 技,2001,8(4)：206-209.
[31]曹书华.血必净对感染性多器官功能障碍综合征大鼠组织及内皮操作保护作用的研究[J].中国危重病急救医学,2002,12(8)：489-491.
[32]杨峰,陈斌.归元创疗汤对严重创伤患者血浆内毒素、TNF-α及IL-6的影响[J].广东医学,2007,(28)5：828-830.
[33]薛长连,吴力克.骨及软组织损伤时白细胞介素-1β与白细胞介素6变化及清热活血消肿合剂的干预效应[J],中国组织工程研究与临床康复,2007,(11)41：8408-8410.
[34]薛长连,吴力克.清热活血消肿Ⅰ、Ⅱ合剂对软组织损伤白细胞介素-1β和白细胞介素-6的影响[J].中国中医骨伤科杂志,2004,(12)3：22-24.
[35]薛长连,吴力克.清热活血消肿合剂Ⅰ、Ⅱ对软组织损伤患者血清肿瘤坏死因子和C反应蛋白的影响[J].中国临床康复,2004,(20)8：4058-4059.
[36]孙国荣,肖四旺.桃红四物汤对膝关节置换术后血清IL-2、IL-6、TNF-α表达水平的影响[J].湖南中医药大学学报,2008,(28)3：32-34.
[37]蓝肇熙,马忆南.损伤血瘀证与IL26、IL210的相关性及化瘀中药对其影响的实验研究[J].四川中医,2008,(26)11：17-19.
[38]薛长连,万年宇,徐青镭.清热活血消肿Ⅰ,Ⅱ合剂改善闭合性骨伤合并软组织损伤的疼痛肿胀[J].中国临床康复,2003,7(11)：1738.
[39]魏定基.临床使用甘露醇的不良反应分析[J].临床合理药.2010,3(1)：29-30.
[40]马民,陈利国.活血止痛散治疗骨折术后肿胀90例[J].时珍国医国药,2006,17(1)：89.
[41]叶俊材,张俐,吕一.活血化瘀汤对大鼠骨折周围肌肉肿胀的影响[J].浙江中医杂志,2007,(42)9：542.
[42]高学敏等.中药学(M).中国中医药出版社(第7版),2002,345-375.
[43]吴雪晖,罗飞,谢肇.丹红注射液治疗四肢长骨骨折术后肿胀的疗效观察[J],中华中医药学刊,2008,26(4)：893-894.
[44]程卫珍,骨折创伤后便秘的中医辨证施护[J].现代中西医结合杂志,2008,17(17)：2702-2703.
[45]吕卫华,杨朝霞,龚美霞.骨折卧床患者发生便秘的原因分析及护理干预[J].中国误诊学杂志,2008,8(32)：7924-7925.
[46]吴秋萍,钱忆.骨折卧床患者便秘的原因分析与护理对策[J].现代中西医结合杂志,2009,18(18)：2196-2197.
[47]许国根,陈雯,张万光.全身炎症反应综合征患者致炎因子与抗炎因子的变化及相关性研究[J].中国急救医学,2002,(22)6：320-321.
[48]姚咏明.多器官功能障碍综合征发病机制研究新进展[J].中华急诊医学杂 志,2001,10(1)：63.
[49]李越华.中医药干预全身炎症反应综合征研究概况[J].辽宁中医杂志,2009,(36)3：89-490.
[50]蒋超.辨证分型治疗全身炎症反应综合征疗效观察[J].中国中西医结合外科杂志,2004,(11)4：245-247.
[51]郑敏宇,何颂华.全身炎症反应综合征的中西医治疗进展[J].上海中医药杂志,2007,41(3)：78-79.
[52]张永和,赵宁,宋祖军.多发性创伤后血清TNF-α、IL-1β、IL-6及IL-10变化的连续观察.中国急救医学2002,22(3)143-144.
[53]Florian Gebhard, MD, Helga Pfetsch, MSc, Geralf Steinbach, MD. tIs interleukin 6 an Early Marker of injury Severity Following Major Trauma in Humans?[J]. Aach surg,2000,135,291-295.
[54]Panagiotis V Giannoudis, Malcolm R Smith, Robert T Evans. Serum CRP and IL-6 levels after trauma not predictive of septic complication in 31 patients[J],Acta Orthop Scand,1998,69(2)184-188.
[55]石莹,王晓勇.血必净对全身炎症反应综合征的治疗作用[J],浙江中医药大学学报,2009,(33)4：497-498.
[56]高学敏等.中药学(M).中国中医药出版社(第7版),2002,166.
[57]王宇,周杰.丹参对大鼠移植肝脏再灌注损伤中TNF-α及IL-1水平的影响[J].山东大学学报,2009,47(4)：54-57.
[58]马志胜,沈文律.中药丹参、生脉治疗全身炎症反应综合征的实验研究[J].中国普外基础与临床杂志,2005,12(4)：395-397.
[59]姜莉,赵仓焕.用控制论思想看辨证论治[J].江苏中医药,2008,(40)6：16-18.
[60]章柏平,张晓云,倪健毛.严重创伤患者血工L-6、IL-8和TNF-α的动态变化[J].实用临床医学,2008,9(8)：4-8.
[61]侯文远,重度创伤患者细胞因子变化及临床意义[J].中国实用医药,2008,(3)21：10-11.
[62]汪毅,周勇.多发性创伤患者细胞因子变化及临床意义[J].现代医药卫生,2006,(22)8：1115-1116.
[63]程三放,陆宏伟,李小珍.严重创伤患者TNF、IL-6和IL-10水平的变化及其临床意义[J].陕西医学杂志2003,(32)5：407.
[64]Ten Dijke, Fu J, Schaap P, et al. Signal transduction of bone morphogenetic proteins in osteoblast differentiation[J]. J Bone Joint Surg,2003,85:34.
[65]SchafersM, Geis C, Brors D, et al. Anterograde transport of tumor necrosis factor2alpha in the intact and injured rat sciatic nerve [J]. J Neurosci,2002,22(2):536-545.
[66]陈振兵,洪光祥,王发斌.肿瘤坏死因子对周围神经损伤后感觉神经元的保护作用[J].中华手外科杂志,2000,(16)2：120-122.
[67]姚魁武,王阶.血瘀证量化诊断流行病学调查数据的主成分分析[J].辽宁中医杂志,2009,36(1)：30-32.
[68]杨超,周岩,孙晓红,等.具有中医“热毒血瘀证”表征的大鼠血液成分和流变学变化.中国比较医学杂志,2007,17(10)：607.
[69]Hayrettin Ozturk, Yusuf Yagmur, Hulya Ozturk.The prognostic importance of serum IL-lb, IL-6, IL-8and TNF-a levels compared to trauma scoring systems for early mortality in children with blunt trauma [J]. Pediatr Surg Int (2008) 24:235-239.
[70]郭奇峰,徐中和,温世锋.血清肿瘤坏死因子a及白细胞介素6水平对下肢严重创伤病情变化的预测价值[J].中国临床康复,2006,10(24)：114-116.
[71]张喜平,李昱,吴斗,等.机械性创伤患者血清IL-6、TNF-α的动态变化及其意义[J].中国急救医学,2001,(21)11：635-637.